Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Sponsor:
Boston Scientific Corporation
Brief Summary:
The purpose of this registry is to compile characteristics of world-wide outcomes for the use
of Boston Scientific’s commercially available Vercise DBS system in the treatment of
Parkinson’s disease.
of Boston Scientific’s commercially available Vercise DBS system in the treatment of
Parkinson’s disease.
Additionally, the utilization of Guide XT (GXT) System when used as a planning tool for the
programming of patients with the Boston Scientific’s Vercise DBS Systems is also evaluated.
Criteria
Key Inclusion Criteria:
– Meets criteria established in locally applicable Vercise System Direction for Use
– At least 18 years old
Key Exclusion Criteria:
– Meets any contraindication in the Vercise System locally applicable Directions for Use
Subjects with significant cognitive or psychiatric impairment may be excluded in the
evaluation of GXT.
Locations
- Boston Scientific Clinical Research Toll-Free Number, Valencia, California, United States, 91355
